HRP20180078T1 - VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE - Google Patents
VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE Download PDFInfo
- Publication number
- HRP20180078T1 HRP20180078T1 HRP20180078TT HRP20180078T HRP20180078T1 HR P20180078 T1 HRP20180078 T1 HR P20180078T1 HR P20180078T T HRP20180078T T HR P20180078TT HR P20180078 T HRP20180078 T HR P20180078T HR P20180078 T1 HRP20180078 T1 HR P20180078T1
- Authority
- HR
- Croatia
- Prior art keywords
- human monoclonal
- igg antibody
- range
- isolated human
- monoclonal igg
- Prior art date
Links
- 238000006467 substitution reaction Methods 0.000 claims 2
- 101000653189 Homo sapiens Tissue factor pathway inhibitor Proteins 0.000 claims 1
- 102220471540 Single-stranded DNA cytosine deaminase_Y31H_mutation Human genes 0.000 claims 1
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 claims 1
- 102220244279 rs373241693 Human genes 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (2)
1. Terapijski pripravak koji sadrži izolirano ljudsko monoklonsko IgG protutijelo koje se specifično veže na ljudski inhibitor faktora tkivnog puta (TFPI), naznačen time da
sekvenca teškog lanca izoliranog ljudskog monoklonskog IgG protutijela je SEQ ID NO: 10, i
sekvenca lakog lanca izoliranog ljudskog monoklonskog IgG protutijela je SEQ ID NO: 17, te
izolirano ljudsko monoklonsko IgG protutijelo sadrži Y31H supstituciju u lakom lancu.
2. Izolirano ljudsko monoklonsko IgG protutijelo prema zahtjevu 1, naznačeno time da teški lanac navedenog protutijela obuhvaća histidinsku supstituciju koja je odabrana iz skupine koju čine Y102H, Y32H i Y100H, te njihove kombinacije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798261P | 2013-03-15 | 2013-03-15 | |
| EP14729504.2A EP2970497B1 (en) | 2013-03-15 | 2014-03-14 | Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics |
| PCT/US2014/029048 WO2014144577A1 (en) | 2013-03-15 | 2014-03-14 | Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180078T1 true HRP20180078T1 (hr) | 2018-03-09 |
Family
ID=50928243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180078TT HRP20180078T1 (hr) | 2013-03-15 | 2018-01-16 | VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9556280B2 (hr) |
| EP (1) | EP2970497B1 (hr) |
| JP (4) | JP6454678B2 (hr) |
| CN (2) | CN105452298B (hr) |
| CA (1) | CA2906128A1 (hr) |
| CY (1) | CY1120210T1 (hr) |
| DK (1) | DK2970497T3 (hr) |
| ES (1) | ES2657304T3 (hr) |
| HK (1) | HK1218128A1 (hr) |
| HR (1) | HRP20180078T1 (hr) |
| HU (1) | HUE037907T2 (hr) |
| LT (1) | LT2970497T (hr) |
| NO (1) | NO3022387T3 (hr) |
| PL (1) | PL2970497T3 (hr) |
| PT (1) | PT2970497T (hr) |
| RS (1) | RS56814B1 (hr) |
| SI (1) | SI2970497T1 (hr) |
| WO (1) | WO2014144577A1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| WO2012115241A1 (ja) | 2011-02-25 | 2012-08-30 | 中外製薬株式会社 | FcγRIIb特異的Fc抗体 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
| US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
| CN105102618B (zh) | 2012-12-27 | 2018-04-17 | 中外制药株式会社 | 异源二聚化多肽 |
| KR20210130260A (ko) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Ｆｃ영역 개변체 |
| CN107108726A (zh) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| EP3262075B1 (en) * | 2015-02-25 | 2024-03-13 | Mogam Institute For Biomedical Research | Novel antibody binding to tfpi and composition comprising the same |
| CN107922506B (zh) | 2015-08-19 | 2021-11-09 | 辉瑞公司 | 组织因子途径抑制剂抗体及其用途 |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| KR20210074335A (ko) | 2018-10-11 | 2021-06-21 | 화이자 인코포레이티드 | Tfpi 길항제의 투여량 섭생법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588507A (en) * | 2008-04-11 | 2012-11-30 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| UA112050C2 (uk) | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| JP5714505B2 (ja) | 2008-12-22 | 2015-05-07 | ノヴォ ノルディスク アー／エス | 組織因子経路阻害因子に対する抗体 |
| NZ602115A (en) | 2010-03-01 | 2014-12-24 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
| SG10201507722QA (en) * | 2010-03-11 | 2015-10-29 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| DK2694544T3 (en) | 2011-04-01 | 2019-04-15 | Bayer Healthcare Llc | MONOCLONAL ANTIBODIES AGAINST TIBI FACTOR ACTIVITY INHIBITOR (TFPI) |
| WO2013148248A1 (en) * | 2012-03-30 | 2013-10-03 | Bayer Healthcare Llc | Protease-regulated antibodies |
| CA2881679C (en) * | 2012-08-13 | 2021-01-26 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| AU2013302966B2 (en) * | 2012-08-15 | 2017-06-08 | Lucid, Inc. | Systems and methods for imaging tissue |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2014
- 2014-03-14 US US14/213,278 patent/US9556280B2/en active Active
- 2014-03-14 CN CN201480016248.5A patent/CN105452298B/zh not_active Expired - Fee Related
- 2014-03-14 LT LTEP14729504.2T patent/LT2970497T/lt unknown
- 2014-03-14 RS RS20180073A patent/RS56814B1/sr unknown
- 2014-03-14 PL PL14729504T patent/PL2970497T3/pl unknown
- 2014-03-14 EP EP14729504.2A patent/EP2970497B1/en active Active
- 2014-03-14 US US14/772,336 patent/US20160009818A1/en not_active Abandoned
- 2014-03-14 PT PT147295042T patent/PT2970497T/pt unknown
- 2014-03-14 CN CN202110987812.XA patent/CN113788897A/zh active Pending
- 2014-03-14 HU HUE14729504A patent/HUE037907T2/hu unknown
- 2014-03-14 CA CA2906128A patent/CA2906128A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/029048 patent/WO2014144577A1/en active Application Filing
- 2014-03-14 SI SI201430564T patent/SI2970497T1/en unknown
- 2014-03-14 ES ES14729504.2T patent/ES2657304T3/es active Active
- 2014-03-14 JP JP2016502971A patent/JP6454678B2/ja not_active Expired - Fee Related
- 2014-03-14 DK DK14729504.2T patent/DK2970497T3/da active
- 2014-07-03 NO NO14826414A patent/NO3022387T3/no unknown
-
2016
- 2016-06-02 HK HK16106252.2A patent/HK1218128A1/zh unknown
-
2018
- 2018-01-16 HR HRP20180078TT patent/HRP20180078T1/hr unknown
- 2018-01-24 CY CY20181100096T patent/CY1120210T1/el unknown
- 2018-04-25 US US15/962,624 patent/US20180282430A1/en not_active Abandoned
- 2018-12-17 JP JP2018235059A patent/JP6697064B2/ja not_active Expired - Fee Related
-
2020
- 2020-01-24 JP JP2020009685A patent/JP2020079250A/ja active Pending
-
2021
- 2021-04-16 JP JP2021069872A patent/JP2021107436A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PT2970497T (pt) | 2018-01-30 |
| JP2016514683A (ja) | 2016-05-23 |
| CN105452298A (zh) | 2016-03-30 |
| US20180282430A1 (en) | 2018-10-04 |
| JP2021107436A (ja) | 2021-07-29 |
| US9556280B2 (en) | 2017-01-31 |
| JP2019069973A (ja) | 2019-05-09 |
| JP6454678B2 (ja) | 2019-01-16 |
| RS56814B1 (sr) | 2018-04-30 |
| CN105452298B (zh) | 2021-08-31 |
| JP6697064B2 (ja) | 2020-05-20 |
| LT2970497T (lt) | 2018-03-12 |
| WO2014144577A1 (en) | 2014-09-18 |
| SI2970497T1 (en) | 2018-04-30 |
| NO3022387T3 (hr) | 2018-08-25 |
| HK1218128A1 (zh) | 2017-02-03 |
| ES2657304T3 (es) | 2018-03-02 |
| PL2970497T3 (pl) | 2018-05-30 |
| CY1120210T1 (el) | 2018-12-12 |
| HUE037907T2 (hu) | 2018-09-28 |
| DK2970497T3 (da) | 2018-01-29 |
| JP2020079250A (ja) | 2020-05-28 |
| CA2906128A1 (en) | 2014-09-18 |
| CN113788897A (zh) | 2021-12-14 |
| US20140275493A1 (en) | 2014-09-18 |
| EP2970497A1 (en) | 2016-01-20 |
| EP2970497B1 (en) | 2017-10-25 |
| US20160009818A1 (en) | 2016-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180078T1 (hr) | VARIJANTE ANTI-TFPI PROTUTIJELA S DIFERENCIJALNIM VEZANJEM U ŠIROKOM RASPONU pH RADI POBOLJŠANE FARMAKOKINETIKE | |
| HRP20192295T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi) | |
| HRP20191775T1 (hr) | Multispecifične konstrukcije antitijela | |
| CU20170169A7 (es) | Anticuerpos de factor xi | |
| CY1120849T1 (el) | Αντισωμα που συνδεεται σε ανθρωπινο cd3 | |
| EA201692504A1 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| CL2011002756A1 (es) | Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad. | |
| EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| EA201591153A1 (ru) | Антитела, связывающиеся с tl1a, и их применение | |
| BR112016002199B8 (pt) | Anticorpo que se liga a um complexo de hgarp e tgf-b1 latente, composição compreendendo o mesmo, uso e linhagem celular de hibridoma | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| AR076193A1 (es) | Anticuerpos biespecificos trivalentes | |
| HRP20221262T1 (hr) | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava | |
| EA201301108A1 (ru) | Биспецифические связывающие молекулы, связывающиеся с vegf и ang2 | |
| EA201201227A1 (ru) | Бипаратопные а-бета-связывающие полипептиды | |
| BR112013028908A2 (pt) | anticorpos c-kit e usos dos mesmos | |
| BR112013031485A8 (pt) | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais | |
| UA110358C2 (en) | Molecules of antibody binding il-17a and il-17f | |
| EA201401065A1 (ru) | Ang2-связывающие молекулы | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
| MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. |